{
    "Trade/Device Name(s)": [
        "Access Toxo IgG"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K242022",
    "Predicate Device Reference 510(k) Number(s)": [
        "K080869"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LGD"
    ],
    "Summary Letter Date": "July 10, 2024",
    "Summary Letter Received Date": "July 11, 2024",
    "Submission Date": "March 25, 2025",
    "Regulation Number(s)": [
        "21 CFR 866.3780"
    ],
    "Regulation Name(s)": [
        "Toxoplasma gondii serological reagents"
    ],
    "Analyte Class(es)": [
        "serology",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibody to Toxoplasma gondii"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Paramagnetic-particle chemiluminescent immunoassay",
        "Automated",
        "Two-step immunoenzymatic assay"
    ],
    "Methodologies": [
        "Chemiluminescent immunoassay",
        "Enzyme Linked Immunoabsorbent Assay (ELISA)"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for Access Toxo IgG paramagnetic-particle chemiluminescent immunoassay for detection of IgG antibodies to Toxoplasma gondii in serum using the DxI 9000 Access Immunoassay Analyzer",
    "Indications for Use Summary": "Qualitative and quantitative determination of IgG antibodies to Toxoplasma gondii in human serum to aid in diagnosis of infection and assess immune status of pregnant women; not intended for blood/plasma donor screening or use with immunocompromised patients, cord blood, neonates, or infants.",
    "fda_folder": "Microbiology"
}